Insider Transactions in Q1 2023 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2023
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,669
-0.33%
|
$21,352
$8.55 P/Share
|
|
Feb 01
2023
|
Michael Secora Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
210,163
+10.67%
|
-
|
|
Feb 01
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600
+0.0%
|
$4,200
$7.97 P/Share
|
|
Jan 26
2023
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
8,000
-3.78%
|
$64,000
$8.07 P/Share
|
|
Jan 26
2023
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.64%
|
$8,000
$1.06 P/Share
|
|
Jan 26
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
7,886
+0.06%
|
$55,202
$7.99 P/Share
|
|
Jan 25
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
24,526
+0.2%
|
$171,682
$7.88 P/Share
|
|
Jan 24
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$71,080
$8.71 P/Share
|
|
Jan 17
2023
|
Shafique Virani Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-12.03%
|
$90,000
$9.16 P/Share
|
|
Jan 17
2023
|
Shafique Virani Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.67%
|
$10,000
$2.22 P/Share
|
|
Jan 10
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
69,518
+0.56%
|
$486,626
$7.72 P/Share
|
|
Jan 10
2023
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
8,885
-0.12%
|
$62,195
$7.69 P/Share
|
|
Jan 09
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
76,046
+0.62%
|
$532,322
$7.64 P/Share
|
|
Jan 06
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
68,953
+0.56%
|
$482,671
$7.41 P/Share
|
|
Jan 05
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
3,000
-0.31%
|
-
|
|
Jan 05
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
21,500
+1.8%
|
-
|
|
Jan 05
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,035
+0.66%
|
$560,245
$7.38 P/Share
|
|
Jan 05
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
2,500
-100.0%
|
$17,500
$7.38 P/Share
|
|
Jan 05
2023
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
2,500
+50.0%
|
-
|
|
Jan 05
2023
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,500
-3.4%
|
$129,500
$7.39 P/Share
|
|
Jan 04
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
91,892
+0.76%
|
$643,244
$7.8 P/Share
|
|
Jan 03
2023
|
Investment CO Pjsc Mubadala > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
141,646
+1.17%
|
$991,522
$7.5 P/Share
|
|
Jan 03
2023
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,573
+0.25%
|
-
|
|
Jan 03
2023
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,483
+6.51%
|
-
|
|
Jan 03
2023
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,821
+1.13%
|
-
|
|
Jan 03
2023
|
Zachary Bogue Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,407
+18.03%
|
-
|
|
Jan 03
2023
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,325
+0.02%
|
-
|